Onstin

Onstin is a clinical-stage biotechnology company headquartered in Suzhou, China, specializing in the development of novel small molecule drugs for oncology. The company's primary focus is on the DNA damage response (DDR) pathway, with a lead candidate, ONST-001, which acts as a highly selective inhibitor of Ubiquitin-specific protease 1 (USP1). ONST-001 is currently undergoing Phase 1 clinical evaluation for patients with advanced solid tumors, particularly those with specific genetic alterations like BRCA mutations. Onstin aims to address unmet medical needs by developing therapies that can be used as monotherapy or in combination with existing treatments like PARP inhibitors. The company is backed by prominent venture capital firms and maintains research and development facilities in both Suzhou and Shanghai.